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Abstract
Background: Increasing morbidity and mortality from colorectal cancer is evident in recent years in the developing
Asian nations. Particularly in Thailand and most neighbouring low-income countries, screening colonoscopy is not
yet recommended nor implemented at the national policy level.
Methods: Screening colonoscopy was offered to 1,500 healthy volunteers aged 50–65 years old who were registered
into the program between July 2009 and June 2010. Biopsy and surgery was performed depending on the identified
lesions. Fecal immunochemical tests (FIT) were additionally performed for comparison with colonoscopy.
Results: There were 1,404 participants who underwent colonoscopy. The mean age of the cohort was 56.9 ± 4.2 years
and 69.4 % were females. About 30 % (411 cases) of all colonoscopies had abnormal colonoscopic findings, and of
these, 256 cases had adenomatous polyps. High risk adenomas (villous or tubulovillous or high grade dysplasia or
size > 1 cm or > 3 adenomatous polyps) were found in 98 cases (7 %), low risk adenoma in 158 cases (11.3 %), and
hyperplastic polyps in 119 cases (8.5 %). Eighteen cases (1.3 %) had colorectal cancer and 90 % of them (16 cases) were
non-metastatic including five stage 0 cases, seven stage I cases, and four stage IIA cases. Only two cases had
metastasis: one to regional lymph nodes (stage IIIB) and another to other organs (stage IVA). The most common cancer
site was the distal intestine including rectum (7 cases, 38.9 %) and sigmoid colon (7 cases, 38.9 %). Ten colorectal
cancer cases had positive FIT whereas 8 colorectal cancer cases were FIT-negative. The sensitivity and specificity of FIT
was 55.6 % and 96.2 %, respectively, while the positive predictive value was 16.4 % and negative predictive value was
99.4 %. The overall survival of colorectal cancer cases at 5-year was 83.3 %.
Conclusion: High prevalence of colorectal cancer and high-risk adenoma was found in the Thai population aged 50–65
years old by screening colonoscopy. FIT was not sensitive enough to detect colorectal cancer in this asymptomatic
cohort. Integration of screening colonoscopy into the national cancer screening program should be implemented to
detect early cases of advanced colorectal neoplasia and improve survival of colorectal cancer patients in Thailand.
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Background
Colorectal cancer is one of the most common causes of
cancer death globally each year, along with lung, liver,
prostate, and breast cancer [1]. Disease incidence of
economically developed countries in Asia such as Japan,
Korea and Singapore abruptly approached the level of
the Western countries. Data from the National Cancer
Institute of Thailand Cancer Registry also showed a
gradual increase in the number of new colorectal cancer
patients in recent years with increased advance stage
cases identified [2]. Colorectal cancer screening can
diagnose cases in early stages, decrease cancer mortality
and potentially prevent this disease [3, 4]. Detection and
proper management of advanced colorectal neoplasia
which included malignant and some high risk colorectal
lesions that need therapeutic interventions should prevent
progression and worse outcomes in the affected cases.
Colonoscopy is one of the cancer screening tests that
achieves goals of premalignant and early stage cancer
detection and when it is coupled with polypectomy, it
can prevent and reduce the incidence of disease, and fi-
nally of all results, decrease mortality from colorectal
cancer [3–5]. Therefore, colonoscopy is recommended
in colorectal cancer screening guideline since 1997 [6].
However, screening colonoscopy is presently not in-
cluded in the national colorectal cancer screening policy
in Thailand nor widely recommended for the Thai popu-
lation. Most previous studies utilized fecal immuno-
chemical test (FIT) as a first screening tool although the
majority of the Thai population do not undergo such
testing on a regular basis [7–9]. This study aimed to
provide essential information on consideration of imple-
mentation of a nation-wide colorectal cancer screening
program in Thailand and developing countries. Screen-
ing colonoscopy was performed as a first screening tool
in all cases while FIT was done as a comparison.
Methods
Study participants
After the study protocol had been approved by the
Human Research Ethical Committee of Chulabhorn
Research Institute, we enrolled participants between 50
and 65 years of age with no past medical history of
colorectal cancer or poorly controlled underlying dis-
eases in July 2009. In total, 1,612 applicants expressed
their willingness to participate in this project. All partici-
pants were educated about colorectal cancer and screen-
ing methods that were to be used in this study as well as
study objectives, details of each procedure including
possible complications, and usage of data from the study.
Some patients were excluded based on age, poor medical
problem control, or the inability to be followed over a
long-term period. Finally, 1,404 participants underwent
colonoscopy between July 2009 and June 2010 after they
provided informed consent. Their demographic data,
medical history, physical examination, and pre-operative
management were collected.
Screening colonoscopy and pathological diagnosis
Bowel preparation before colonoscopy was established
by using 90 mL of sodium phosphate after a low fiber
diet for 2 days. All participants underwent colonoscopy
under intravenous anaesthesia. The colonoscopic findings
in each colonic section were recorded. If abnormal muco-
sal findings or polyps were found, the removed tissue was
sent for pathological diagnosis. We categorized abnormal
tissue from colonoscopic findings and pathological reports
into malignant, high-risk adenoma, low risk adenoma, and
non-adenomatous polyps, for which each group under-
went different appropriate management according to
National Comprehensive Cancer Network (NCCN) guide-
lines for colorectal cancer screening. High-risk adenoma
cases recommended to have repeat colonoscopy earlier
than low risk adenoma cases included one of the following
colonoscopic and pathological criteria: size ≥1 cm, ≥3 ad-
enomas, or tubulovillous or villous adenoma or high grade
dysplasia. All malignant cases were diagnosed by patho-
logical staging using the Seventh edition of the Union for
International Cancer Control (UICC) TNM Classification
of Malignant Tumours [10]. Patients with colorectal can-
cer were treated according to the NCCN Guidelines [11].
Participants without malignancy were seen annually in the
clinic for general evaluation, and FIT and follow-up colon-
oscopy was to be performed based on clinical findings and
colorectal cancer risks. The second screening colonoscopy
was respectively performed at 3, 4, and 5 years follow-up
for high risk adenoma cases, low risk adenoma/hyperplas-
tic polyp cases, and normal colonoscopy cases.
Screening fecal immunochemical test (FIT)
FIT was performed in parallel to screening colonoscopy by
fecal occult blood (FOB) one-step test device, a rapid chro-
matographic immunoassay (Abon Biopharm Hangzhou,
China) with relative sensitivity of 93.6 % and relative speci-
ficity of 99.1 % [12, 13]. The FOB one-step test can detect
fecal blood as low as 50 ng/mL or 6 μg/g feces and is
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specific for human hemoglobin at a concentration of
1.0 mg/mL. Fecal specimens were self-collected from the
first bowel movement in the morning of the appointed date
for FIT test which occurred before the start of bowel
preparation for screening colonoscopy. The specimens
were stored in a clean and dry container and brought in to
the hospital by the participants at environmental
temperature. The participants were instructed to hand in
the samples to the laboratory within 6 h of collection.
Statistical analysis
Statistical analyses were performed with STATA version
12.1. Data of the participants were reported as means
and standard deviation for continuous variables and as
proportions and absolute counts for categorical variables.
We also estimated FIT sensitivity, specificity and predictive
values in detecting colorectal cancer.
Results
Demographic characteristics of the study cohort
Of the 1,404 participants, there were 429 males and 975
females, with a mean age of 56.9 ± 4.2 years. Most
(81.8 %) of the participants lived in Bangkok Metropol-
itan and connective territorial provinces during the time
of the colonoscopy. Overall, 96.1 % of participants had
no lower gastrointestinal symptoms, i.e. bowel habit
changes or lower gastrointestinal bleeding or decreased
stool calibre or anemia, and the majority (91.7 %) did not
have a family history of colorectal cancer, respectively
(Table 1). Complete colonoscopy was accomplished in
99.6 % (1,399) of cases. In five incomplete colonoscopy
cases, patients were further investigated by CT colonogra-
phy, all of which produced normal findings.
Screening colonoscopy findings
About 30 % (411 cases) of all colonoscopies had abnormal
colonoscopic findings. Malignancy was found in 1.3 % (18
cases) of all cases. Of all colonoscopies, 18.2 % (256 cases)
had adenomatous polyps, of which 7 % (98 cases) were
high risk adenoma. The other 9.8 % (137 cases) had
abnormal tissue, of which 8.5 % (119 cases) were hyper-
plastic polyps (Fig. 1). The pathological diagnosis of malig-
nant tissue in this study showed two cases of carcinoid
tumor out of 18 cases. Others were adenocarcinoma with
stages varying from stage 0 to stage 4 (Table 2). Nearly
90 % (16 cases) were non-metastatic colorectal cancer; five
stage 0 cases, seven stage I cases, and four stage IIA cases.
Only two cases from our study had metastasis: one to
regional lymph nodes (stage IIIB) and another to other
organs (stage IVA). Most abnormalities that required
tissue diagnosis were found in the left side of the colon
(Fig. 2). The most common cancer site was rectum (7
cases, 38.9 %) and sigmoid colon (7 cases, 38.9 %). Also,
the most common site for high risk adenoma and low risk
adenoma was sigmoid colon (30 % and 35 %, respectively)
and the second most common sites were ascending and
transverse colon. Most adenoma had only low grade dys-
plasia. Only one case of high grade dysplasia was detected
in a tubulovillous adenoma case. The gender proportion
in 256 cases of adenoma group was 117 males (45.7 %)
and 139 females (54.3 %). For colorectal cancer cases, they
were 8 males (44.4 %) and 10 females (55.6 %).
Table 3 summarizes histopathology findings of 55
cases with complaining symptoms that may have sug-
gested cancer at the outset of screening and 117 cases
with a family history of colorectal cancer. Among 55
cases, 3 developed colorectal cancer (5.5 %) as compared
with 15 cases in asymptomatic cases (1.1 %) (p = 0.031).
Various types of adenomas and polyps were also found
in symptomatic cases. If symptomatic cases were
excluded, high risk adenoma and colorectal cancer
accounted for 8.15 % (110/1,349 cases). Four colorectal
cancer cases developed in participants with a family his-
tory of colorectal cancer (3.4 %) whereas 14 colorectal
cancer cases (1.1 %) were found in a no family history
group (p = 0.056). Hyperplastic polyps tended to be more
common in participants with a family history of colorec-
tal cancer.
Sensitivity and specificity of FIT in diagnosis of colorectal
cancer
As shown in Table 4, 10/18 colorectal cancer cases had
positive FIT whereas 8 colorectal cancer cases were FIT-
negative. The sensitivity and specificity of FIT in detection
of colorectal cancer was 55.6 % and 96.2 %, respectively,
while the positive predictive value (PPV) was 16.4 % and





Age 56.9 ± 4.2
BMI
> 25 640 (45.6)
≤ 25 764 (54.4)
Area
Bangkok and territories 1148 (81.8)
Other 256 (18.2)
Lower gastrointestinal tract symptoms
Yes 55 (3.9)
No 1349 (96.1)
Family history of colorectal cancer
Yes 117 (8.3)
No 1287 (91.7)
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the negative predictive value (NPV) was 99.4 %. Table 5
shows the distribution of FIT-positivity among participants
with various histopathology findings. Most of adenoma
cases were FIT-negative. FIT-positive non-cancer cases
included6 high risk adenoma, 3 low risk adenoma, 8 hyper-
plastic polyps, and 33 cases with normal colonoscopy
results.
Follow-up of study participants and survival of colorectal
cancer cases
In the follow-up period after colonoscopic screening,
there were three additional new cases of colorectal
cancer. Two cases of intramucosal carcinoma of sigmoid
colon and another case with stage 1 anal canal adenocar-
cinoma were found in the second year from the group
previously identified as high risk adenoma, low risk aden-
oma and hyperplastic polyp, respectively. The mortality
due to colorectal cancer cases in this study was 3/18 cases:
1 case with stage IV disease died in the first year, 1 case
with stage IIA in the fourth year, and another case in stage
I died from unrelated primary hepatobiliary cancer. The
overall survival of colorectal cancer cases at 5 year was
83.3 % (88.9 % if excluded 1 death from unrelated cancer).
Discussion
The discovery rate of high risk adenoma and invasive
colorectal cancer in this study (8.15 %) was nearly twice
that of advanced colorectal neoplasia in the asymptom-
atic population (4.5 %) as reported from multiple studies
in Asia but comparable to that of the symptomatic
population (7.8 %) [14]. These patients should receive
therapeutic intervention before progression to more ad-
vanced disease. When we excluded the amount criteria
from the high risk adenoma group, the prevalence of
advanced colorectal neoplasia in our study (3 %) and
also adenocarcinoma (1.3 %) were still comparable to
the country with a high incidence of colorectal cancer
[14, 15]. Prior hospital-based reports and retrospective
Fig. 1 Pathological diagnosis from screening colonoscopy; aincluding inflammatory polyp, colitis, lipoma and loss specimens; bincluding diverticulosis
without biopsied tissues and hemorrhoids
Table 2 Staging and 5-year survival rates of 18 colorectal cancer










5-year survival rate 15 (83.3)a
aOne case died from unrelated hepatobiliarycancer
Fig. 2 Anatomical site distribution of abnormal colonic tissue from
screening colonoscopy
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studies from Thailand also showedcancer detection rate
by colonoscopy of 0.6–7.1 % in different studied popula-
tion [7–9, 16, 17]. These previous studies utilized FIT as a
first screening tool and were unlike our study whereby
colonoscopy was performed as a first screening tool.
The abnormal colonic tissue (29.3 %) findings from
our screening colonoscopy study are in the range of
polyp detection rates (25–37 %) reported in other
studies from within and outside Thailand [16–20]. Both
adenomatous polyp and hyperplastic polyposis can accu-
mulate worse genetic changes and become malignant
[21, 22]. Therefore, colorectal cancer screening would
benefit this population. Although most abnormalities
that required tissue diagnosis were found in the left side
of the colon, complete colonoscopy should be done to
include low and high risk adenomas in the second most
common locations, the transverse and ascending colon.
There are some key differences in the selection of
subjects for our study compared with others: our study
included screening criteria for an age group at high risk
of colorectal cancer [23], while others included data
from a symptom-related group. Moreover, this result
might not represent the incidence of colorectal cancer
from all regions in Thailand because most (81.8 %) of
the participants were from the Bangkok metropolitan
region and territories. If this finding represented the real
incidence of colorectal cancer in our population, or
perhaps even in urban and suburban areas, launching a
national colorectal cancer screening policy should be
considered for specific groups. Other factors that might
affect a high yield of colorectal cancer findings include
public information that may stimulate awareness and
access to reluctant cancer patients.
Problems related to colonoscopy screening include its
invasiveness, complications, high financial cost, and need
of specialized endoscopists; these reasons were reported
as causes of low colorectal screening adherence in well
Table 3 Histological comparison between cases with or without symptoms at screening day 0 visit and between cases with or without
family history of colorectal cancer











Colorectal cancer 3 (5.5) 15 (1.1) 0.031b 4 (3.4) 14 (1.1) 0.056b
Stage
0 1 4 2 3
I 0 6 0 6
IIA 1 4 1 4
IIIB 0 1 1 0
IVA 1 0 0 1
High risk adenoma 3 (5.5) 95 (7.0) 0 (0.0) 98 (7.6)
Low risk adenoma 10 (18.2) 148 (11.0) 13 (11.1) 145 (11.3)
Hyperplastic polyp 3 (5.5) 116 (8.6) 14 (12.0) 105 (8.2)
Other pathological diagnosisa 0 (0.0) 18 (1.3) 2 (1.7) 16 (1.2)
No colorectal tumor 36 (65.5) 957 (70.9) 84 (71.8) 909 (70.6)
aInflammatory polyp, colitis, and lipoma
bFisher Exact Test







aFIT not done in 40 cases
Sensitivity (55.6 %), Specificity (96.2 %), PPV (16.4 %), NPV (99.4 %)







Colorectal cancer 10 (16.4) 8 (0.6)
High risk adenoma 6 (9.8) 87 (6.7)
Low risk adenoma 3 (4.9) 152 (11.7)
Hyperplastic polyp 8 (13.1) 106 (8.1)
Other pathological diagnosisb 1 (1.6) 17 (1.3)
No colorectal tumor 33 (54.1) 933 (71.6)
aFIT not done in 40 cases
bInflammatory polyp, colitis, lipoma
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developed countries [24, 25]. Therefore, other more
practical screening methods were utilized instead of col-
onoscopy. The sensitivity of FIT for cancer detection in
our study (55 %) was comparable to Guaiac fecal occult
blood test (37–79 %) but somewhat lower than results of
FIT in other studies (79 %) [26, 27]. In some resource-
limited countries, fecal-based screening may play a major
role in decreasing colorectal cancer mortality with high
subject acceptance rates [28, 29]. However, in our study,
the sensitivity of FIT of 55.6 % was deemed inadequate to
detect colorectal cancer cases and 8/18 cancer cases had
negative FITs.
There are no recommendations for any other surveil-
lance procedure after screening colonoscopy, but endo-
scopic management after colonoscopic and pathologic
findings have been suggested [30–34]. However, in this
study, cases of colorectal cancer were found before the
recommended period of surveillance colonoscopy, which
were similar to the findings of other studies [5, 24, 35–39].
Moreover, some cases also suffered from unrelated types
of cancer. Thus, some individual risk criteria such as
smoking, a family history of biliary tract cancer which are
common in Thailand should be concerned for improve-
ment of screening benefits in specific groups of patients
[40, 41]. Quality indices [42, 43], technology of colonos-
copy [44] and other predictors [45–48] should be included
for detection of these interval cancers. Particularly, with
the aging population in Thailand, proper screening and
surveillance programsneed to be further evaluated [3].
The mortality caused by colorectal cancer in our study
after monitoring for 5 years was only two cases from colo-
rectal cancer. Another case died from unrelated hepatobili-
ary cancer. So the 5-yearsurvival rate after screening
colonoscopy and standard treatment of detected colorectal
cancer cases in this study, even including five cases (27.8 %)
with stage IIA and IIIB, was excellent at 88.9 %. This sur-
vival rate was comparable to survival of stage I colorectal
cancer (87–92 %) after standard staging and treatment [49].
Conclusions
In our study population aged 50–65 years old, 30 % of
colonoscopically screened cases had abnormal colonic
lesions that needed further pathological diagnosis. The
colorectal cancer detection rate was 1.3 % and the overall
prevalence of advanced colorectal neoplasia was 3 % by
screening colonoscopy. Tissue abnormalities were found
more in the distal part than the proximal part of the large
intestine. The overall survival of colorectal cancer patients
diagnosed by colonoscopic screening was 83 %. FIT was
inadequate to detect advanced colorectal neoplasia and
missed almost half of the colorectal cases. We suggest that
screening colonoscopy should be implemented as part of
the National Colorectal Cancer Screening Program in
Thailand.
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